Mangla, Kamal Kant
Novo Nordisk (Denmark)
2 papers on CoChatORCID 0000-0002-3613-2748
Most cited papers
- Verified
Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor
Evans, M., Husain, M., Srivastava, A., Mangla, K. K., Kuhlman, A. B., & Lingvay, I. (2024) · Advances in Therapy
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 13
- Verified
TOP-309 Identifying patient characteristics associated with the risk of long-term liver and cardiovascular outcomes and high healthcare costs in metabolic dysfunction-associated steatohepatitis: a retrospective cohort analysis using an artificial intelligence model
Mangla, K. K., Gbadamosi, S., Semeniuta, D., Soule, B., Nordahl, H., Bandaria, J., Zabinski, J., Curhan, G., & Boussios, C. (2024) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free